Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Chronic activation of a designer Gq-coupled receptor improves β cell function
Shalini Jain, … , Jean-Marc Guettier, Jürgen Wess
Shalini Jain, … , Jean-Marc Guettier, Jürgen Wess
Published March 8, 2013
Citation Information: J Clin Invest. 2013;123(4):1750-1762. https://doi.org/10.1172/JCI66432.
View: Text | PDF
Research Article Endocrinology

Chronic activation of a designer Gq-coupled receptor improves β cell function

  • Text
  • PDF
Abstract

Type 2 diabetes (T2D) has emerged as a major threat to human health in most parts of the world. Therapeutic strategies aimed at improving pancreatic β cell function are predicted to prove beneficial for the treatment of T2D. In the present study, we demonstrate that drug-mediated, chronic, and selective activation of β cell Gq signaling greatly improve β cell function and glucose homeostasis in mice. These beneficial metabolic effects were accompanied by the enhanced expression of many genes critical for β cell function, maintenance, and differentiation. By employing a combination of in vivo and in vitro approaches, we identified a novel β cell pathway through which receptor-activated Gq leads to the sequential activation of ERK1/2 and IRS2 signaling, thus triggering a series of events that greatly improve β cell function. Importantly, we found that chronic stimulation of a designer Gq-coupled receptor selectively expressed in β cells prevented both streptozotocin-induced diabetes and the metabolic deficits associated with the consumption of a high-fat diet in mice. Since β cells are endowed with numerous receptors that mediate their cellular effects via activation of Gq-type G proteins, our findings provide a rational basis for the development of novel antidiabetic drugs targeting this class of receptors.

Authors

Shalini Jain, Inigo Ruiz de Azua, Huiyan Lu, Morris F. White, Jean-Marc Guettier, Jürgen Wess

×

Figure 3

M3 muscarinic receptor/Rq-mediated increases in Irs2 expression are PLC, PKC, and ERK1/2 dependent.

Options: View larger image (or click on image) Download as PowerPoint
M3 muscarinic receptor/Rq-mediated increases in Irs2 expression are PLC,...
(A and B) Treatment of INS1-M3 insulinoma cells with OXO-M, a muscarinic agonist, has no effect on intracellular cAMP levels (A), but leads to pronounced increases in intracellular calcium concentrations (B). The curves shown are representative of 3 independent experiments. (C) Incubation of INS1-M3 cells with OXO-M (100 μM; 5 hours) results in a robust increase in Irs2 mRNA expression that can be blocked by atropine (10 μM), a muscarinic antagonist. Forskolin (10 μM), a direct activator of adenylyl cyclase, causes a response of similar magnitude. (D) Pharmacological inhibitors of PLC (U73122, 10 μM), PKC (GF109203X, 2.5 μM), and MEK1/2 (U0126, 10 μM) prevent or greatly reduce the OXO-M–induced (100 μM) increase in Irs2 expression in INS1-M3 cells. (E) siRNA-mediated knockdown of ERK1/2 expression abolishes the OXO-M–induced (100 μM) increase in Irs2 expression in INS1-M3 cells. (F and G) Incubation of isolated islets prepared from β-Rq mice with CNO (1 μM) results in a robust increase in Irs2 mRNA levels (3 hours CNO incubation; F) and ERK1/2 phosphorylation in islet lysates (10 minutes CNO incubation; G). These effects were not observed after treatment of islets with inhibitors of PLC, PKC, or MEK1/2 (see above; also see the legend to Figure 2 for additional experimental details). Data represent mean ± SEM of 2 or 3 independent experiments (G shows representative Western blots). *P < 0.05; **P < 0.01; ***P < 0.001.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts